Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

@article{Suzuki2013PrognosticVO,
  title={Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone},
  author={Kazuhito Suzuki and Yasuhito Terui and Masahiro Yokoyama and Kyoko Ueda and Noriko Nishimura and Yuko Mishima and Sakura Sakajiri and Naoko Tsuyama and Kengo Takeuchi and Kiyohiko Hatake},
  journal={Leukemia \& Lymphoma},
  year={2013},
  volume={54},
  pages={2412 - 2417}
}
Abstract The purpose of this study was to investigate prognostic factors for overall survival (OS) among patients with previously untreated diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP). We evaluated four biological parameters, including thymidine kinase (TK) activity. This study included 183 patients. The median level of TK was 14.0 IU/L, which we chose as the cut-off. After a median follow-up time of 50.0… 

Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL).

  • B. LiuBo Li Jianmin Yang
  • Medicine
    Clinica chimica acta; international journal of clinical chemistry
  • 2018

Beta‐2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B‐cell lymphoma

TLDR
A new prognostic index composed of age, performance status, stage, and B2MG could stratify the outcomes of patients with DLBCL effectively and appears to be a valuable risk model for these patients.

There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma

TLDR
Since high TK activity correlated with inferior clinical response as well as inferior progression-free and overall survival after treatment with R-CHOP, the authors suggest that this is most likely to be due to a more malignant tumor phenotype present in a highly proliferative status of the lymphoma.

References

SHOWING 1-10 OF 64 REFERENCES

High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone

Abstract The prognosis of patients with peripheral T-cell lymphoma (PTCL) treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) is poor, but their laboratory prognostic

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

  • J. RuanP. Martin J. Leonard
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
Bortezomib with R-CHOP-21 can be safely administered and may enhance outcomes, particularly in non-GCB DLBCL, justifying randomized studies and IPI and MIPI correlated with survival inDLBCL and MCL.

High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma

TLDR
Serum thymidine kinase 1 levels may help to refine risk assessment in the modern immunotherapy era by identifying high TK1 levels as a prognostic factor for overall survival and progression-free survival independent of FLIPI score variables.

R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group.

TLDR
R-CHOEP-14 is a promising regimen for young patients with high-risk DLBCL with improved OS and PFS compared with R-CHOP-14, and this is the first study comparing these two regimens in this patient group.

Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL)

TLDR
GEM-P is an effective second-line regimen in patients with relapsed or refractory DLBCL and the addition of Rituximab appears to further improve outcomes.

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

  • M. RobertsonB. Kahl M. Shipp
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Treatment with enzastaurin was well-tolerated and associated with prolonged FFP in a small subset of patients with relapsed or refractory DLBCL.

High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.

TLDR
High-dose sequential therapy is superior to standard-dose MACOP-B for patients with diffuse large-cell lymphoma of the B-cell type and overall survival at seven years is marginally significant.

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

TLDR
This is the first report of substantial activity of temsirolimus in lymphomas other than mantle cell lymphoma, and supports further evaluation of mTOR as a target in these diseases.

Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase.

TLDR
The addition of thymidine kinase permits a more precise estimate of risk, contributing to the utility of a serological staging system for large cell lymphoma.

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

TLDR
High-dose chemotherapy with autologous stem-cell support with standard regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone is superior to CHOP in adults with disseminated aggressive lymphoma in a randomized trial.
...